This is a phase I/II multicenter study to evaluate the safety and efficacy of JSKN033 in Chinese subjects with unresectable locally advanced/metastatic solid tumors.
Be able to understand informed consent form, voluntarily participate and sign informed consent form.
Age ≥18 year (at the time consent is obtained), male or female.
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Has a Life expectancy ≥3 months.
Has clinically active brain metastases.
Previously received any other investigational drug within 28 days prior to enrollment.
Previously received local palliative treatment within 14 days prior to enrollment.
Previously received major surgeries within 28 days prior to enrollment.